Loading
DPYD (Dihydropyrimidine dehydrogenase [NADP(+)]) is an enzyme. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Head and neck squamous cell carcinoma and Gastric & gastro-oesophageal junction cancer. This dossier gathers the 1 product (0 approved), 13 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Catalyses the reduction of uracil and thymine in the initial step of reductive pyrimidine catabolism, a pathway that yields beta-alanine from uracil and beta-aminoisobutyrate from thymine. Also capable of degrading the chemotherapeutic drug 5-fluorouracil. Location: Cytoplasm, cytosol (UniProt). Locus 1p21.3 (HGNC).
| Modality | Withdrawn or failed |
|---|---|
| Chemotherapy 1 |
| Trial | Setting | Result | Products | ||
|---|---|---|---|---|---|
CAIRO5 NCT02162563 | 3 | Mixed | Initially unresectable colorectal liver metastases, stratified by sidedness and RAS/BRAF status: a doublet plus bevacizumab, FOLFOXIRI plus bevacizumab, or a doublet plus panitumumab, with central resectability review every two months | FOLFOXIRI plus bevacizumab better than a doublet for right-sided or RAS/BRAF-mutant disease; panitumumab no better than bevacizumab for left-sided wild-type disease. | |
TRIBE2 NCT02339116 | 3 | Positive | Untreated metastatic colorectal cancer: upfront FOLFOXIRI plus bevacizumab with reintroduction after progression, against sequential mFOLFOX6 then FOLFIRI, each with bevacizumab | Progression-free survival 2 of 19.2 against 16.4 months (hazard ratio 0.74). | |
TRIBE NCT00719797 | 3 | Positive | Untreated metastatic colorectal cancer: FOLFOXIRI plus bevacizumab against FOLFIRI plus bevacizumab | Progression-free survival 12.1 against 9.7 months (hazard ratio 0.75); response rate 65 against 53 percent. | |
| 3 | Planned | Adjuvant Modified FOLFOXIRI Versus mFOLFOX6 in Patients With Postoperative MRD Positive Stage II-III Colorectal Cancer: A Multicenter, Open Lable Randomized Phase 3 Study (AFFORD) | - | ||
| 3 | Planned | MEND-IT II: Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy, Followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer. | - | ||
| 3 | Recruiting | Neoadjuvant FOLFOXIRI Chemotherapy Versus CapeOX Chemotherapy for Local Advanced Rectal Cancer: An Open Label Randomized Controlled Phase III Trial | - | ||
| 3 | Recruiting | Post-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer Prospective, Randomized, Open, Multicenter Phase III Trial to Investigate the Efficacy of Active Post-resection/Ablation Therapy in Patients With Metastatic Colorectal Cancer | - | ||
| 3 | Planned | Pre-Operative Treatment in REseCTable COlon CanceR (PROTECTOR/FIRE-10; AIO-KRK-0620; IAG-VO-0323) Prospective, Randomized, Open, Multicenter Phase III Trial to Investigate the Efficacy Preoperative Systemic Therapy in Advanced Colon Cancer | - | ||
| 3 | Recruiting | Prospectively Randomized Control Clinical Trial of FOLFOXIRI Preoperative Chemotherapy Alone on Rectal Cancer in Local Advance Comparing to Oral Capecitabine Combined With Long-term Radiation | - | ||
| 2 | Planned | A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation | - | ||
| 2 | Recruiting | Value of CtDNA in Surveillance of Adjuvant Chemosensitivity and Regimen Adjustment in Stage III Colon Cancer: a Phase II Randomized Controlled Trial (REVISE Trial) | - | ||
| 2 | Planned | Neoadjuvant mFOLFOXIRI Plus Bevacizumab for Organ Preservation in Locally Advanced Rectal Cancer: A Singe-arm Phase II Study | - | ||
| 2 | Recruiting | Neoadjuvant Treatment With mFOLFOXIRI Plus Cadonilimab (AK104) Versus mFOLFOX6 Alone in Locally Advanced Colorectal Cancer: a Randomized Control Phase II Study (OPTICAL-2) | - |
No recorded escape route names this target.
No pathway diagram carries this target as a node.
No companion diagnostic in the registry measures this target.
No model entry for this target yet; check the cancer entries on the models page.
No open questions recorded for this target yet. Suggest one.
Query for this target: (TITLE:"DPYD" OR ABSTRACT:"DPYD" OR TITLE:"dihydropyrimidine dehydrogenase" OR ABSTRACT:"dihydropyrimidine dehydrogenase" OR TITLE:"Dihydropyrimidine dehydrogenase [NADP + ]" OR ABSTRACT:"Dihydropyrimidine dehydrogenase [NADP + ]" OR TITLE:"DHPDHase" OR ABSTRACT:"DHPDHase") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about DPYD, not a curated reading list.
The dossier as machine-readable JSON, at /api/v1/dossiers/dpyd.json: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/dpyd.json. Licence CC BY-NC 4.0.